The reduction in receptor activity conferred by the point mutations of EPHA3 found in cancers, and ligand- and EPHA3-dependent apoptosis of tumor and stroma cells upon receptor agonist treatment suggested that wild-type EPHA3 has anti-tumorigenic properties in NSCLC [19, 43–46]. Here, EPHA3 is linked to non-small cell lung carcinoma.